Connect Biopharma Holdings (CNTB) EBIT Margin (2024 - 2026)
Connect Biopharma Holdings' (CNTB) quarterly EBIT Margin came in at 635.98% in Q2 2026, up 2733068.0% year-over-year from N/an in Q2 2025, and up 94.52% quarter-over-quarter from 11601.78% in Q1 2026.
Powered by 
Analysis
Connect Biopharma Holdings (CNTB) EBIT Margin (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has disclosed EBIT Margin across 3 years of filings, most recently posting 635.98% for Q2 2026.
- In Q2 2026, EBIT Margin rose 2733068.0% year-over-year to 635.98%; the TTM figure through Jun 2026 stood at 2384.49% (up 7536.0% YoY), while the FY2025 annual figure was 90740.62%, down 9065438.0% from the prior year.
- EBIT Margin came in at 635.98% for Q2 2026 at Connect Biopharma Holdings, up from 11601.78% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 635.98% in Q2 2026 to a low of 110481.25% in Q3 2025.
- Average EBIT Margin over 3 years is 25533.27%, with a median of 6489.93% recorded in 2024.
- Year-over-year, EBIT Margin slumped 10934540 bps in 2025 and jumped 2733068 bps in 2026.
- Over 3 years, EBIT Margin stood at 1378.08% in 2024, then sank by 7917 bps to 110481.25% in 2025, then surged by 99 bps to 635.98% in 2026.
- Per Business Quant data, the three most recent EBIT Margin figures were 635.98% in Q2 2026, 11601.78% in Q1 2026, and 110481.25% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Connect Biopharma Holdings | 129.86 Mn | 129.86 Mn | - | -635.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -635.98% |
| Mar 31, 2026 | -11,601.78% |
| Sep 30, 2025 | -110,481.25% |
| Jun 30, 2025 | -27,966.67% |
| Dec 31, 2024 | -1,378.08% |
| Sep 30, 2024 | -1,135.85% |